Kura Oncology, Inc. KURA

KURA Company Overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer treatment. The company operates within the oncology and biotechnology industries, with an emphasis on targeted therapies designed to address genetically defined cancers and to improve outcomes for patients with significant unmet medical needs. Kura’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, and financing activities, as the company has not yet commercialized a product based on publicly available filings through 2025. Its research programs primarily target kinase signaling pathways, menin interactions, and other molecular drivers associated with hematologic malignancies and solid tumors.

The company was founded in 2014 and is headquartered in San Diego, California. Kura evolved through the acquisition and advancement of targeted oncology assets, building a pipeline centered on precision oncology and combination therapy strategies. Its strategic positioning is tied to expertise in molecularly targeted cancer therapies and collaborations with larger pharmaceutical companies to support development and commercialization capabilities. Key pipeline programs have included ziftomenib, a menin inhibitor being developed for genetically defined acute leukemias, and tipifarnib, a farnesyl transferase inhibitor studied across several oncology indications.